View Cart (0 items)
Pharmaceutical

UK rejects Bristol-Myers’ skin cancer drug

October 14, 2011
/ Print / Reprints /
| Share More
/ Text Size+

LONDON — Britain’s National Institute for Health and Clinical Excellence recommended Friday that Bristol-Myers Squibb Co.’s skin-cancer treatment Yervoy not be used due to uncertainty about the product’s longer-term benefits, its side effects and its cost, MarketWatch reported.

The draft guidance on the medicine is now open for consultation until Nov. 4 before further decisions on the therapy are made.

The drug is intended to help patients with advanced melanoma live longer.
You must login or register in order to post a comment.